Hyperarousal in insomnia and hypnotic dose escalation

Sleep Medicine ◽

10.1016/j.sleep.2016.06.008 ◽

2016 ◽

Vol 23 ◽

pp. 16-20 ◽

Author(s):

T.A. Roehrs ◽

T. Roth

Keyword(s):

Dose Escalation ◽

Download Full-text

326 The practice of 2 hour observation following dose escalation of beta-blocker therapy is not necessary

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(05)80211-5 ◽

2005 ◽

Vol 4 (1) ◽

pp. 76-76

Keyword(s):

Dose Escalation ◽

Beta Blocker ◽

Blocker Therapy ◽

Beta Blocker Therapy

Download Full-text

Palliative Care Pearls: Opioid Dose Escalation in the Treatment of End-of-Life Pain

PsycEXTRA Dataset ◽

10.1037/e507242006-006 ◽

2003 ◽

Author(s):

Judith A. Kitzes ◽

Keyword(s):

Palliative Care ◽

End Of Life ◽

Dose Escalation ◽

Download Full-text

DOSE ESCALATION OF BIOLOGICS IN CROHN'S DISEASE: CRITICAL REVIEW OF OBSERVATIONAL STUDIES

10.26226/morressier.57c5383cd462b80296c9b2f3 ◽

2016 ◽

Author(s):

Xin Ying Lee

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Dose Escalation ◽

Critical Review ◽

Observational Studies

Download Full-text

Use of Two Technologies, Singulex Single Molecule Counting (SMC)TMand Meso Scale Discovery&[reg](MSD) Technology for Drug Levels Determination of an Antibody Therapeutic, MK-A, in Human Serum in a Dose Escalation Study

10.26226/morressier.57d6b2bbd462b8028d88cc5b ◽

2016 ◽

Author(s):

Phyllis Conliffe

Keyword(s):

Human Serum ◽

Single Molecule ◽

Dose Escalation ◽

Meso Scale Discovery ◽

Dose Escalation Study ◽

Drug Levels ◽

Download Full-text

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

Case Medical Research ◽

10.31525/ct1-nct03998345 ◽

2019 ◽

Author(s):

Keyword(s):

Dose Escalation ◽

Phase 1 ◽

Dose Escalation Study ◽

Download Full-text

Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Case Medical Research ◽

10.31525/ct1-nct04139434 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Oral Administration ◽

Dose Escalation ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Chronic Myelomonocytic Leukemia ◽

Dose Escalation Study ◽

Myelomonocytic Leukemia ◽

Download Full-text

An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Case Medical Research ◽

10.31525/ct1-nct04278768 ◽

2020 ◽

Author(s):

Keyword(s):

Myelodysplastic Syndrome ◽

Dose Escalation ◽

Acute Myelogenous Leukemia ◽

Myelogenous Leukemia ◽

Acute Myelogenous

Download Full-text

Faculty Opinions recommendation of Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1043078.492991 ◽

2006 ◽

Author(s):

Jeffrey Evans

Keyword(s):

Protein Kinase C ◽

Protein Kinase ◽

Phase I ◽

Advanced Cancer ◽

Pharmacokinetic Study ◽

Dose Escalation ◽

Kinase C ◽

Protein Kinase C Beta

Download Full-text

Faculty Opinions recommendation of Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1083008.535984 ◽

2007 ◽

Author(s):

Per Aspenberg

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Dose Escalation ◽

Human Fibroblast ◽

Bone Repair ◽

Prospective Trial ◽

Local Application ◽

Fibroblast Growth Factor 2 ◽

Fibroblast Growth

Download Full-text

Faculty Opinions recommendation of Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1162910.623534 ◽

2009 ◽

Author(s):

Ulf Müller-Ladner

Keyword(s):

Tumour Necrosis Factor ◽

Dose Escalation ◽

Inflammatory Arthritis ◽

Tumour Necrosis ◽

Phase 1 ◽

Tumour Necrosis Factor Alpha ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Alpha Antagonist ◽

Necrosis Factor

Download Full-text